TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01223339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Dose escalation of 1, 5, and 25 mg Ertugliflozin administered in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Dose escalation of 1, 5, and 25 mg Ertugliflozin administered in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets to Ertugliflozin administered in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Ertugliflozin 25 mg tablets administered once daily in the fed state for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets administered once daily in the fed state for 7 days
Study: NCT01027962

Intervention type: OTHER
Group type: OTHER
Intervention: ICBT Program
Description: Intensive Computerized Brain Training.
Study: NCT05407207

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Tennant Biomodulator ®
Description: Tennant Biomodulator ® (Avazzia, Inc., Texas, USA)(FDA Classification: 882.5890 Neurology, Biofeedback device) is FDA-cleared for symptomatic relief and management of chronic pain. The device is simply activated using device buttons and does not need to be adjusted or monitored once therapy begins, making it easy for the purpose of therapy under unsupervised conditions or for use in busy HD clinics. The device will be used with FDA-cleared TENS electrodes that will be connected to the device via wires, providing an electrically conductive interface between the device and the subject's skin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tennant Biomodulator ®
Description: Tennant Biomodulator ® (Avazzia, Inc., Texas, USA)(FDA Classification: 882.5890 Neurology, Biofeedback device) is FDA-cleared for symptomatic relief and management of chronic pain. The device is simply activated using device buttons and does not need to be adjusted or monitored once therapy begins, making it easy for the purpose of therapy under unsupervised conditions or for use in busy HD clinics. The device will be used with FDA-cleared TENS electrodes that will be connected to the device via wires, providing an electrically conductive interface between the device and the subject's skin.
Study: NCT02059564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM11260C
Description: doses of 6 mg, 16 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM11260C
Description: doses of 6 mg, 16 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Victoza
Description: doses of 1.8 mg
Study: NCT01169480

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Give a massage
Description: Participants in this arm will give a 50-minute Swedish massage to a volunteer.
Study: NCT02276430

Intervention type: OTHER
Intervention: Vena punction
Description: Once 90 ml

Intervention type: OTHER
Intervention: Vena punction
Description: Once 90 ml
Study: NCT04168567

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Microbiome analysis
Description: Samples from the vagina, endometrium and anus and analyzing microbiome with NGS technique.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Microbiome analysis
Description: Samples from the vagina, endometrium and anus and analyzing microbiome with NGS technique.
Study: NCT02148068

Intervention type: PROCEDURE
Intervention: Bariatric Surgery
Description: Patients enrolled will undergo either a laparoscopic Roux-en-y Gastric Bypass or laparoscopic Sleeve Gastrectomy. The determination of which operation performed will be made independent of patients' enrollment in the study.

Intervention type: PROCEDURE
Intervention: Bariatric Surgery
Description: Patients enrolled will undergo either a laparoscopic Roux-en-y Gastric Bypass or laparoscopic Sleeve Gastrectomy. The determination of which operation performed will be made independent of patients' enrollment in the study.
Study: NCT00386620

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: 45 minute survey about health, pain and relationships

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Feedback on use of handheld computer electronic diaries (ED).
Study: NCT04644510

Intervention type: DEVICE
Intervention: Lung ultrasonography
Description: Standardized eight-point Lung ultrasonography
Study: NCT00976716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Day 1~* The first dose: Celecoxib 400mg~* The second dose: Celecoxib 200mg during a period between 6 hours post-first dose and before bed~Days 2 to 8 (Study drug should be taken until the dose scheduled after breakfast on the day of Day 8)~- Celecoxib 200mg twice daily
Study: NCT00828503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Certican (everolimus) + valganciclovir
Description: Oral MED 1: Certican® initial dose: 1,5-3 mg day target trough level: 3-8 ng/mL (first levels will be performed after 3 days and then adjusted until - according to the judgement of the clinical investigator - a stable degree of immunosuppression is reached; thereafter Certican® trough levels will be performed at the scheduled appointments)~MED 2: Valganciclovir (or ganciclovir) will be administered in addition to Certican (valganciclovir: 450 mg twice daily, ganciclovir 5 mg/kg i.v. twice daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir
Description: Valganciclovir (or ganciclovir) will be administered alone (valganciclovir: 450 mg twice daily, ganciclovir 5 mg/kg i.v. twice daily)
Study: NCT01473303

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ganitumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Completed on paper
Study: NCT03805971

Intervention type: DEVICE
Intervention: Study of the pleural cavity with a confocal laser endomicroscope.
Description: Probe based confocal laser endomicroscope can be introduced through the working chanel of the thoracoscope. this allows the study of the pleural cavity with this new tool.
Study: NCT04624217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701
Description: PDL1/TGFβ
Study: NCT02670018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemigliptin and metformin HCl extended release
Description: Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg \* 2 tablets, for 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemigliptin/metformin HCl extended release
Description: Administration of combination of gemigliptin 25mg/metformin HCl extended release 1000mg \* 2 tablets, for 1day
Study: NCT03998904

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle preservation
Description: Muscle preservation during graft preparation of hamstring graft
Study: NCT04099628

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rapid diagnostic test (RDT); Serological and molecular tests on DBS
Description: The population of low to zero prevalence HAT foci will be actively screened for HAT by taking a blood sample for performing 3 rapid diagnostic tests (RDT) and for preparing dried blood spots to perform 4 serological and molecular high throughput reference tests. If at least one of the RDTs, serological or molecular reference tests is positive, parasitological examination is performed twice. The combined results of parasitological examinations serve as reference standard.~Other Names:~rHAT Sero-Strip (Coris Bioconcept, Belgium) SD Bioline HAT 1.0 (Standard Diagnostics Korea) HAT Sero-K-Set (Coris Bioconcept, Belgium) Immune trypanolysis: presence of antibodies ELISA: on native LiTat 1.3 + LiTat 1.5 variant surface glycoprotein (VSG) LAMP T. brucei Detection Kit (Eiken) RT-PCR: Trypanozoon 18S, Tbg Trypanosoma gambiense specific glycoprotein (TgsGP)
Study: NCT01218113

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals HIV Vaccine 732462
Description: 2 or 3 doses according to protocol schedule
Study: NCT03998904

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No muscle preservation
Description: No muscle preservation during graft preparation of hamstring graft
Study: NCT01837017

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Exercise
Description: This is a control group with no intervention
Study: NCT01218113

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals HIV Vaccine 732462
Description: 2 or 3 doses according to protocol schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 or 3 doses according to protocol schedule
Study: NCT00885885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab+FOLFOX-4
Description: Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes.~A cycle of panitumumab is defined as 14 days.~FOLFOX 4 chemotherapy will be administered on day 1 of each 14-day treatment cycle:~* Oxaliplatin 85mg/m2 as a 120 minute infusion on day 1 of each cycle~* Folinic acid 200mg/m2 as a 120 minute infusion on days 1 and 2~* A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on days 1 and 2~* 5-FU at 600mg/m2 as a continuous infusion of 22 hour infusion on days 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab+FOLFIRI
Description: Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes.~A cycle of panitumumab is defined as 14 days.~FOLFIRI chemotherapy will be administered on day 1 of each 14-day treatment cycle:~* Irinotecan 180 mg/m2 will be administered over 90 minutes ± 15 minutes on day 1 of each cycle~* Folinic acid 400 mg/m2 will be administered over 2 hours ± 15 minutes during the irinotecan infusion but without mixing~* A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on day 1~* 5-FU at 2400 mg/m2 continuous intravenous infusion over 46-hour ± 2-hour on day 1 of each cycle.
Study: NCT04202978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab ：200mg intravenous injection d1 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Apatinib：250mg/d P.O ,qd ,3weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: capecitabine:850mg/m2 P.O ,bid ,d1-d14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: oxaliplatin:130mg/m2 intravenous injection d1 q3w

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Description: radiofrequency ablation:between first cycle and second cycle percutaneous
Study: NCT03972826

Intervention type: OTHER
Group type: OTHER
Intervention: Provodine
Description: Subjects serve as self-controls. Subjects first perform hand-hygiene with alcohol-based hand rub then doff gloves contaminated with either S. marcescens or MS2 phage and the hands are cultured using a bag-broth method to determine whether the subjects self-contaminated while doffing. Subjects then clean their hands thoroughly, perform hand hygiene with Provodine, then repeat the doffing and culture process.
Study: NCT00884715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: short acting octreotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: short acting octreotide
Study: NCT01109550

Intervention type: PROCEDURE
Intervention: ERCP
Description: endoscopic retrograde cholangiopancreatography transpapillary biopsies

Intervention type: PROCEDURE
Intervention: ERCP
Description: endoscopic retrograde cholangiopancreatography transpapillary biopsies
Study: NCT02562872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSM265
Description: DSM265 400 mg single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSM265
Description: DSM265 400 mg single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSM265
Description: DSM265 400 mg single oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match DSM265, single oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match DSM265, single oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match DSM265, single oral dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sporozoites
Description: Direct venous inoculation of 3200 cryopreserved Plasmodium falciparum (NF54 strain) sporozoites

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sporozoites
Description: Direct venous inoculation of 3200 cryopreserved Plasmodium falciparum (NF54 strain) sporozoites

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sporozoites
Description: Direct venous inoculation of 3200 cryopreserved Plasmodium falciparum (NF54 strain) sporozoites

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sporozoites
Description: Direct venous inoculation of 3200 cryopreserved Plasmodium falciparum (NF54 strain) sporozoites

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infective mosquito bite
Description: Five single bites by laboratory reared female Anopheles stephensi mosquitoes carrying Plasmodium falciparum

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Infective mosquito bite
Description: Five single bites by laboratory reared female Anopheles stephensi mosquitoes carrying Plasmodium falciparum
Study: NCT01786863

Intervention type: PROCEDURE
Intervention: Neuromuscular blockade
Study: NCT03374644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SentriTM ETCO2 adult nasal cannula
Description: Sentri nasal cannula is the device which designed to sample exhaled ETCO2 in non-intubated patients during the administration of supplementary oxygen. By delivering oxygen through one prong and sampling exhaled gas from the other prong, the nasal cannula can provide end tidal values comparable to those achieved with intubated patients. It is fitted to the patients as same manner as conventional nasal cannula. Furthermore, it consists of curved prong to improve the anatomical fit.
Study: NCT03934424

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight stigma
Description: Subject will read an article depicting discrimination against individuals with higher body weights for 5-10 minutes on one day

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Ethnic stigma
Description: Subject will read a control article for weight stigma depicting discrimination against individuals from a minority ethnic group for 5-10 minutes on one day
Study: NCT03162393

Intervention type: PROCEDURE
Intervention: nerve transfer

Intervention type: PROCEDURE
Intervention: nerve transfer

Intervention type: PROCEDURE
Intervention: nerve transfer

Intervention type: PROCEDURE
Intervention: nerve transfer

Intervention type: PROCEDURE
Intervention: nerve transfer

Intervention type: PROCEDURE
Intervention: nerve transfer
Study: NCT04480541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Roadmap 2.0 information system
Description: Caregivers and patients download the Roadmap 2.0 app on their own mobile phones/tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wearable activity sensor
Description: Caregivers and patients will receive a Fitbit wearable activity sensor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey administration
Description: Caregivers and patients will be asked to complete health-related quality of life surveys
Study: NCT02747446

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: added sugar
Description: isocaloric substitution of added sugars (honey or FG) for starch

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: added sugar
Description: isocaloric substitution of added sugars (honey or FG) for starch
Study: NCT02339857

Intervention type: PROCEDURE
Intervention: No-touch harvesting technique
Description: The saphenous vein is harvested with a pedicle of surrounding tissue.
Study: NCT02722629

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FEESST
Description: Flexible Endoscopic Evaluation of Swallowing with Sensory Testing
Study: NCT00047307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Undergo 3-dimensional conformal radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02532387

Intervention type: OTHER
Intervention: Telephone follow-up
Description: Prospectively enrolled subjects will have a 7- and 30-day phone call.

Intervention type: OTHER
Intervention: Telephone follow-up
Description: Prospectively enrolled subjects will have a 7- and 30-day phone call.
Study: NCT04077411

Intervention type: OTHER
Intervention: Observational
Description: This is an observational study with no interventions.
Study: NCT01296698

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage Form: Oral NRT; Dose: 0 mg; Frequency: up to 4 times per hour; Duration: 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Dosage Form: Oral NRT; Dose: 1 mg;Frequency: up to four times per hour; Duration:12 weeks
Study: NCT03161782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF stretching
Description: For hold-relax stretching, each subject in PNF Stretching group will be comfortably positioned in a supine lying position, and patient will move the joint to the end of the passive or pain-free ROM. The therapist will ask for an isometric contraction of the restricting muscle or pattern (antagonists) with emphasis on rotation. The patients will be asked to perform submaximal isometric contractions of the target muscle for 10 seconds. After the contraction, the patients will be instructed to relax for 5 seconds. The joint will be repositioned actively to the new limit of range, and then therapist will passively control the new ROM. The procedure will be repeated 10 times with 10 seconds of rest between two successive trials. Patients will be treated 2 times per week for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static Stretching
Description: For static stretching, each subject in Static Stretching group will be comfortably positioned in a supine lying position, and the stretching of target muscle will be maintained for 20 seconds followed by 10 seconds of rest. The procedure will be repeated 10 times with 10 seconds of rest between two successive trials. Patients will be treated 2 times per week for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Shoulder, elbow and wrist AROM exercises. Elbow flexion and extansion self-stretching exercises Elbow and wrist strengthening exercises Proprioception exercises for elbow. Grip strengthening exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Shoulder, elbow and wrist AROM exercises. Elbow flexion and extansion self-stretching exercises Elbow and wrist strengthening exercises Proprioception exercises for elbow. Grip strengthening exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Therapy
Description: Cold therapy will be applied over the elbow for 15 minutes in the form of cold pack after stretching and exercise protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Therapy
Description: Cold therapy will be applied over the elbow for 15 minutes in the form of cold pack after stretching and exercise protocol.
Study: NCT01062919

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Description: patients in the epidural analgesia group will receive ropivacaine 0.2% through the epidural catheter, normal saline in the wound catheter and PCA with morphine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wound catheter
Description: patients in the epidural analgesia group will receive 0.2%ropivacaine through the wound catheter, normal saline in the epidural catheter and PCA with morphine.
Study: NCT02416778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion
Study: NCT01690104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00819104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol XL 50mg + Amlodipine 5mg
Description: tablet,oral,OD,8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol XL 25 mg + Amlodipine 2.5mg
Description: tablet,oral,OD,8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol XL 50mg
Description: tablet,oral,OD,8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol XL 25 mg
Description: tablet,oral,OD,8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 5mg
Description: tablet,oral,OD,8 weeks
Study: NCT03908905

Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnography
Description: Sleep screening, neurocognitive assessment, activity monitoring questionnaires, blood sample
Study: NCT04114539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecopipam
Description: Ecopipam HCl 12.5-, 37.5-. 50-, 75- and 100-mg tablets; 2 mg/kg/day target dose; oral administration daily in evenings.